WO1998004527A1 - Pyranoindole and carbazole inhibitors of cox-2 - Google Patents

Pyranoindole and carbazole inhibitors of cox-2

Info

Publication number
WO1998004527A1
WO1998004527A1 PCT/US1997/012782 US9712782W WO9804527A1 WO 1998004527 A1 WO1998004527 A1 WO 1998004527A1 US 9712782 W US9712782 W US 9712782W WO 9804527 A1 WO9804527 A1 WO 9804527A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
carbon atoms
alkyl
alkenyl
hydrogen
compound
Prior art date
Application number
PCT/US1997/012782
Other languages
French (fr)
Inventor
Anthony Frank Kreft, Iii
Craig Eugene Caufield
Amedeo Arturo Failli
Thomas Joseph Caggiano
Alexander Aleksey Greenfield
Dennis Michael Kubrak
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Abstract

This invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are, each, independently, hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aralkoxy, trifluoroalkoxy, alkanoyloxy, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino, alkanamido, or alkanesulfonamido; R5 is hydrogen, alkyl, alkenyl, alkoxyalkyl or alkylcycloalkyl; R6 is hydrogen, alkyl or alkenyl; X is oxygen or carbon; A is oxygen or NZ; Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonylamino of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, which are useful in the treatment of arthritic disorders, colorectal cancer, and Alzheimer's disease.

Description

PYRANOTNDO E AND CARBAZOLE INHIBITORS OF C X.2

FIELD OF THE INVENTION

This invention is in the fields of antiinflammator and anticancer pharmaceutical agents and specifically relates to compounds, compositions and methods for treating infl.ammation and inflammation-associated disorders, such as arthritis and for treating colorectal cancer.

BACKGROUND OF THE INVENTION

Prostaglandins have been shown to be involved in the pathophysiology of .several chronic human diseases. They are involved as mediators of pain, edema and vascular permeability in arthritic diseases such as rheumatoid arthritis and osteoarthritis (Lewis and Kreft, Immunopharmacol. Immunotoxicol. 17, 607-663 (1995)). In .addition, prostaglandins have been postulated to be involved in the pathophysiology of colorectal cancer (Marcus, New Eng. J. Med. , 333, 656-657 (1995)). Thus an agent that inhibits prostaglandin synthesis may be useful in treating these disorders.

The biosynthesis of prostaglandins was previously thought to be due to the action of a single cyclooxygenase enzyme on arachidonic acid to afford prostaglandin H2 (Vane et al, Postgrad. Med. J. , 66 (Suppl 4), S2-S 17 (1990), Lewis and Kreft, Immunopharmacol. Immunotoxicol. 17, 607-663 (1995)). This intermediate is subsequently transformed into the various members of the prostaglandin family by more distal enzymes. The clinical utility of cyclooxygenase inhibitors (often called NSAIDs: nonsteroidal antiinflammatory drugs) is well established in arthritic disorders (Brooks et al, New Eng. J. Med. , 324, 1716-1725 (1991)); however, these compounds have serious G.I. side effects due to the importance of prostaglandins in the maintenance of gastrointestin functioning and renal blood flow (Dajani et. al., J Physiol .Pharmacol., 46, 3-16 (1995); Somasundaram et al, Scand. J. Gastroenterol., 30, 289-299 (1995)). Under the old paradigm of a single cyclooxygenase enzyme it appeared that the .selective inhibition of prostaglandin synthesis in inflamed tissue versus inhibition of prostaglandin synthesis in G.I tissue was unlikely unless tissue specificity could be achieved .

Recently the discovery that there are two distinct cyclooxygenase enzymes has given rise to a new paradigm which may lead to compounds that have a separation of inhibition of prostaglandin synthesis in inflamed tissue from inhibition of prostaglandin synthesis in G.I tissue (Hayllar, Lancet, 346, 521-522 (1995), Lewis and Kreft, Immunopharmacol. Immunotoxicol. 17, 607-663 (1995)). In the new paradigm the constitutive cyclooxygenase enzyme responsible for prostaglandin synthesis in G.I tissue is termed COX-1 and the inducible cyclooxygenase enzyme responsible for prostaglandin synthesis in inflamed tissue is termed COX-2. Several groups have reported that NSAIDS vary in their ability to inhibit COX- 1 and COX-2 so that selective inhibition may be possible (O'Neill et al, Molec. Pharmacol. , 45, 245-254 (1994); Laneuville et al., J. Pharmacol. Exp. Ther. , 271, 927-934 (1994); Mitchell et al, Proc Natl. Acad. Sci. USA , 90, 11693-11697 (1993)). It is hoped that a selective COX-2 inhibitor would not only have clinical efficacy in inflammatory diseases but also would lack G.I toxicity. There is evidence from animal models to support this hypothesis (Chan et. al., J. Pharmacol Exp.Ther. 21 A, 1531-1537 (1995); Masferrer et. al., Proc. Natl. Acad. Sci. USA , 91, 3228-3232 (1994); Seibert et al . Proc. Natl. Acad. Sci. USA , 91, 12013-12017 (1994)). Moreover, this may be the mechanism behind the improved G.I. srfety of the NSAID etodolac which has a tenfold selectivity for inhibition of COX-2 (Glaser et. al., Eur. J. Pharmacol. 281,107-111 (1995)). Thus novel COX- 2 inhibitors appear as attractive targets for antiarthritic therapy with potential to reduce G.I side effects. In addition, the COX-2 enzyme has been shown to be upregulated in colorectal cancer and a selective COX-2 inhibitor may also be of use in this disease (Sano et. al., Cancer Res., 55, 3785-3789 (1995)). In addition, indomethacin, a relatively non-selective inhibitor of COX -2 with adverse G.I. side effects, has been shown to be useful in the treatment of Alzheimer's disease (Rogers et. al., Neurology, 43, 1609-1611 (1993)) which suggests that a COX-2 selective inhibitor would be not only useful for the treatment of Alzheimer's disease but also a safer therapy with fewer G.I. side effects. Humber et al have described the 10 step synthesis of the 4-oxo analog of the l,3,4,9-tetrahydroρyrano[3,4-b]indole, etodolac {JMed. Chem. 31 , 1712-1719 (1988); U.S. Pat. No. 4,686,213). The 4-oxo metabolite was active in blocking prostaglandin synthesis and had oral in vivo antiinflammatory activity. In this invention we not only describe new analogs of this compound beyond the limited scope of U.S . Patent 4,686,213 but also detail an improved 4 step synthesis for preparing this metabolite as well as previously unknown 4-imino analogs and their activity against the COX-2 enzyme. DESCRIPTION OF THE INVENTION

In accordance with this invention, there .are provided COX-2 inhibitors which are useful as antiarthritic, anticancer and antiAlzheimers agents of formula I:

Figure imgf000005_0001
wherein

Rl, R2, R3 and R4 are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluoroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkylmido of 2-6 carbon atoms, or alkyl sulfonamido of 1-6 carbon atoms; R5 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms; R6 is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms; X is oxygen or carbon;

A is oxygen or NZ;

Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonyamino of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof.

This invention provides both the R and S stereoisomers of the C-1 .alkanoic acid, as well as to mixtures of the R and S stereoisomers. Throughout this application, the n.ame of the product of this invention, where the absolute configuration of the C-1 alkanoic acid is not indicated, is intended to embrace both R and S enantiomers as well as mixtures of the two. The terms alkyl, alkenyl, and alkynyl include both straight chain as well as branched moieties. The term halo includes fluorine, chlorine, bromine, and iodine.

It is preferred that the aryl moiety is a phenyl group which may be optionally mono-, di-, or tri-substituted with a substituent or substituents such as alkyl of 1-6 carbon atoms, arylalkyl of 7-10 carbon atoms, alkoxy of 1-6 carbon atoms, cyano, halogen, nitro, carboidkoxy of 2-7 carbon atoms, -CF3, -OCF3, -OCH2CF3, amino, dialkylamino of 1-6 carbons per alkyl group, alkoxyalkyl of 2-12 carbon atoms, alkylthio of 1-6 carbon atoms, SO3H, PO3H, and CO H.

Preferred compounds of this invention include those in which R5 is hydrogen; those in which Rg is hydrogen and R5 is alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, or alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms; those in which Rg is hydrogen, R5 is .alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, or alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms, and A is oxygen: and those in which R6 is hydrogen, R5 is alkyl of 1-6 carbon atoms, alkenyl of 1-6 carbon atoms, or alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms, X is CH2 or oxygen .and A is NZ where Z is OH or NHSO2alkyl in which each alkyl moiety has 1-6 carbon atoms .

The pharmaceutically acceptable salts include those derived from organic and inorganic acids such as, but not limited to: acetic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, toluenesulfonic and similarly known acceptable acids. Carboxylate salts, preferably alkali metal salts, for example, sodium or lithium, may also be prepared as salts of carboxylic acids where R^ is hydrogen.

The compounds having the formula I as illustrated above where A, R,, R2, R3, R4, R5, R6 and X are as defined above and their pharmaceutically acceptable salts may be prepared by a process which comprises: (a) oxidation of a compound having the formula II

Figure imgf000007_0001

where R,, R2, R3, R4, Rs, R6 and X are as defined above or a salt thereof so as to prepare a compound having the formula I as illustrated above in which A is oxygen and R,, Rj, R3, R4, R5, R6 and X are as defined above or a salt thereof; or

(b) reaction of a compound having the formula I where A is oxygen and R 1 , R2, R3, R4, R5, R6 and X are as defined above or a salt thereof with a compound having the formula H2NZ where Z is as defined above to prepare a compound having formula I as illustrated above where A is NZ and R,, R2, R3, R4, R5, R6, and X are as defined above or a salt thereof; or

(c) hydrolysis of a compound having formula I as illustrated above where A,

R,, R2, R3, R4, R5 and X are as defined above and R6 is alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms so as to form a compound having formula I as illustrated above where A, R,, R2, R3, R4, R5, R6 and X are as defined above and R6 is hydrogen or a salt thereof.

In addition a compound of the invention may be convened into a salt thereof (or such a salt may be converted into a compound of the invention). Such a conversion may be carried out by addition of an acid or a base as appropriate.

The 4-oxo-l,2,3,4-tetrahydro-4H-c.arbazole-l -alkanoic acids of this invention can be conveniently prepared by oxidation of the corresponding carbazole (prepared via Fischer indolization of the appropriate cyclohexanone with the appropriately substituted phenylhydrazine) with either 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (DDQ) or 2,2,6,6-tetramethyl-piperidine-l-oxonium tetrafluoroborate (TEMPO BF4); the related 4-imino compounds can be preferably prepared by reaction of the 4-oxo esters with appropriately substituted amines followed by hydrolysis of the ester moiety (Scheme 1). The starting materials or intermediates are available commercially or can be prepared by standard literature procedures.

Scheme 1

Figure imgf000008_0001

DDQ or TEMPO BF4

Figure imgf000008_0002

4-oxo l,3,4,9-tetrahydropyrano[3,4-b]indole-l-alkanoic acids can be prepared by oxidation of the corresponding l,3,4,9-tetrahydropyrano[3,4-b]indole (prepared, in turn, via cyclization of the appropriately substituted tryptophol with an alkoxy enol ether) with either 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (DDQ) or 2,2,6,6- tetramethyl-piperidine-1-oxonium tetrafluoroborate (TEMPO BF4); the related 4-imino analogs can be preferably prepared by reaction of the 4-oxo esters with various substituted amines followed by hydrolysis of the ester moiety (Scheme 2). Scheme 2

Figure imgf000009_0001

In addition, other functionalized analogs may be prepared by displacement of a bromo substituent such as shown in Scheme 3 (R]=Br).

Figure imgf000010_0001

TEMPO BF4

Figure imgf000010_0002

The compounds of this invention inhibit the COX-2 enzyme which is believed to be responsible for the production of high levels of prostaglandins in inflammation and colorectal cancer (Tables 1-3). It has been shown that selective inhibition of the COX-2 enzyme relative to COX-1 inhibition leads to an antiinflammatory effect without G.I. toxicity (Chan et. al., /. Pharmacol Exp.Ther. 274, 1531-1537 (1995); Masferrer et. al., Proc. Natl. Acad. Sci. USA , 91, 3228-3232 (1994); Seibert et al., Proc. Natl. Acad. Sci. USA , 91, 12013-12017 (1994)). Therefore, the compounds of this invention are useful for the treatment of inflammatory diseases such as rheumatoid arthritis. In addition, compounds that selectively inhibit the COX-2 enzyme are expected to have a greater margin of safety.

The compounds of this invention were evaluated for inhibition of COX-2 and COX-1 as follows: human COX-1 and COX-2 cDNAs were cloned from human monocytes, untreated and LPS treated , respectively, by RT-PCR using oligonucleotide primers based on published rhCOX-1 and rhCOX-2 sequences (Jones et al, J. Biol. Chem., 268, 9049 (1993)). The cDNAs were then transfected into either Sf9 or CHO cells and subsequently converted into a microsomal preparation as described by Glaser et al (Eur. J. Pharmacol. 281, 107-111 (1995)). The microsomal human recombinant enzymes were diluted with buffer (100 mM Tris, pH 7.8 at 37°C) containing 0.5 mM phenol (964 μl total volume). The enzyme preparations were preincubated with vehicle (DMSO) or compounds in DMSO (1% DMSO in final assay) for 30 min at 37°C. Excess hematin was added 1 min prior to initiation of reaction (1.25 μM final hematin) with 30 μM arachidonic acid (sodium salt). Final assay volume was 1.0 ml (100 mM Tris (pH7.8), 0.5 mM phenol, 1.25 μM hematin and 30 μM arachidonic acid at 37°C). The reaction was incubated for 35 s (maximum level of PGH2 accumulation as determined from time course studies), and terminated by addition of 50-60 μl of SnCl2 (1 mg/ml) in 0.1 N HCl. PGH2 is quantitatively converted to PGF2a by this reaction (50% efficiency of total conversion). The pH of each tube is adjusted to pH 3.0-3.5 with IN NaOH and extracted twice with 1.5 ml of ethyl acetate (75-90% efficiency per extraction). Combined ethyl acetate layers were dried under N2 (g) and redissolved in EIA buffer (2.0 ml), and PGF2a was quantified by EIA. The results of the standard pharmacological test procedure described in the preceding paragraphs were as follows:

Table 1 Inhibition of rhCOX- 1 and COX-2 by 4-oxo- 1 ,3,4,9-tetrahydro- pyrano[3,4-b]indoles

Figure imgf000011_0001

Ej am El El Ei % ιnhib of rhCOX-2 αC^ % Inhibition of rhCOX-1

1 H H H Et (2.1 μM) 42% at 90 μM

2 H H H nPr (3.2 μM) 44% at 90 μM

3 H H H CH2OCH3 8% at 3 μM

4 H H Et Et (1.9 μM) (>270 μM) 5 Cl H H Et (1.2 μM)

6 Br H H Et (1.1 μM)

7 CN H H Et 7% at 1 μM

8 H F allyl Et (0.37 μM) 78% at 3 μM R2=H for all compounds in Table 1 Table 2 Inhibition of rhCOX- 1 and COX-2 by 4-oxo- 1 ,2,3,4-tetra- hydro-4H-carbazoles

Figure imgf000012_0001

E&am El El E4 El % Inhib of rhCOX-2 fIC^ % Inhibn of rhCOX-1

9 H H H Et 26% at 3 μM

10 H H Et Et (2.0 μM) 26% at 90 μM

11 H H iPr Et 40% at 3 μM 85% at 90 μM

12 Cl H H Et 12% at 1 μM 5% at 30 μM

13 F H F Et 25% at 1 μM

14 H F F Et (0.7 μM) 50% at 23 μM

15 F H F allyl 30% at 1 μM

16 F H F nPr 29% at 1 μM

17 F F H nPr 13% at 1 μM

R2=H for all compounds in Table 2

Table 3 Inhibition of rhCOX- 1 and COX-2 by 4-imino- 1 ,2,3,4-tetrahydro-4H- carbazoles and l,3,4,9-tetrahydropyrano[3,4-b]indoles

Figure imgf000013_0001

Exam RI R3 R4 R5 X Z Inhib rhCOX-2 % Inhib rhCOX-1

18 H H Et Et O OH 50% at 3.3 μM 96% at 90 μM

19 H H Et Et O NSO2CH3 50% at 3.3 μM* 96% at 90 μM *

20 H H Et Et CH2 OH 18% at l μM R2=H for all compounds in Table 3

* Sodium salt

Based on the results shown in the tables above, the compounds of this invention demonstrated high inhibition of the human COX-2 isozyme and are therefore useful for the treatment of inflammation .and inflammation-associated disorders, as an anticancer agent, and other disease states where a role for the COX-2 enzyme in producing high levels of prostaglandins has been proposed. In particular, the compounds of this invention are useful in treating arthritic disorders, such as rheumatoid arthritis; Alzheimers disea.se; and colorectal cancer .

Certain of the examples in the claims of the invention also demonstrated high selectivity for inhibition of the human COX-2 isozyme and would be expected to have a greater margin of G.I. safety, thereby facilitating patient compliance.

The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintergrating agents or an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets, preferably, contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The amount of therapeutically active compound that is administered and the dosage regimen for treating a specific arthritic disorder or colorectal cancer with the compound and/or compositions of this invention depends on a variety of factors, including the weight, age, sex, medical condition of the subject, the severity of the disease, the route and frequency of administration, and the specific compound employed, .and thus may vary widely. The pharmaceutical compositions may contain active ingredient in the range of 0.1 to 2000 mg, preferably in the range of 0.5 to 500 mg and most preferably between 1 and 100 mg. Projected daily dosages of active compound are 0.01 to 100 mg/kg body weight. The daily dose of can be administered in one to four doses per day.

The following examples illustrate the preparation of representative compounds of this invention.

Example ϊ

Figure imgf000015_0001

π-Ethyl-4-oxo-1.3.4.9-tetrahydro-pyranor3.4-blindol-l-yl)-acetic acid.

To a stirred solution at room temperature under nitrogen of 1 -ethyl- 1,3,4,9- tetrahydro-pyrano[3,4-b]indol-l-yl)-acetic acid methyl ester (Demerson et al J.Med. Chem. 18, 189-191 (1975), 0.271 g, 1 mmol) in 20 ml of dichloromethane-methanol mixture (9:1) was added 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (0.5 g, 2.2 mmol). After 30 min of stirring when TLC showed -90% conversion, the mixture was diluted with water (25 ml), ethyl acetate (50 ml) .and sodium sulfite (10 ml of a 10% solution). The resulting mixture was stirred for -10 min (until substantial discoloration occurred) and diluted with 1 N NaOH solution (20 ml). Extraction with ethyl acetate (50 ml x 3) followed by evaporation of the solvent gave a light brown powder. Purification by flash chromatography (45:55 ethyl acetate:hexane) afforded 0.2 g (70 %) of the methyl ester which gave after hydrolysis (48 h, MeOH/2.5 N NaOH),

0.181 g (95 %) of the desired product as a solid, m.p. 235-238°C. Analvsis for: C15H15NO4

Calculated: C, 65.93; H, 5.53; N, 5.13.

Found: C, 64.81; H, 5.66 ; N, 4.85. lH iME_(400 MHz, DMSO): δ 12.24 (s, 1 H), 12.04 (s, 1 H), 7.2 - 8.1 (m, 4 H), 4.2 - 4.32 (dd, 2 H), 2.8 - 3.1 (dd, 2 H), 1.9 - 2.2 (m, 2 H), 0.83 (t, 3 H). JR_(KBr, cm"1): 3420, 2960, 1720, 1620, 1470. MS [(-)FAB m/z]: (M-H)- 272.

Example 2

Figure imgf000016_0001

(1 -Propvl-4-oxo- 1.3.4.9-tetrahvdro-pvranor3.4-b1indol- 1 -vlVacetic acid. The title compound was prepared from l-propyl-l,3,4,9-tetrahydro- pyrano[3,4-b]indol-l-yl)-acetic acid methyl ester (Demerrøn et al J.Med. Chem. 18, 189-191 (1975), 0.286 g, 1 mmol) using the method of Example 1. Purification by flash chromatography (45:55 ethyl acetate:hexane) afforded 0.226 g (75 %) of the methyl ester which gave after hydrolysis (48 h, MeOH- 2.5 N NaOH) 0.205 g (95 %) of the desired product as a solid, m.p. 206-208°C. Analysis for: C16H17NO4

GalαiM: C, 66.89; H, 5.96; N, 4.87. Found: C, 66.74; H, 5.95; N, 4.73.

1HJSMB 400 MHz, DMSO): 5 12.22 (s, 1 H), 12.02 (s, 1 H), 7.1-8.0 (m, 4 H), 4.2 - 4.4 (dd, 2 H), 2.8 - 3.1 (dd, 2 H), 1.9 - 2.2 (m, 2 H), 1.1 - 1.4 (m, 2 H), 0.85 (t,3 H).

JR KBr, cm"1): 3400, 2950, 1710, 1620, 1460.

MS [(-)FAB m/z]: (M-H)" 287. Example 3

Figure imgf000017_0001

(l-Methoxymethyl-4-oxo-1.3.4.9-tetrahydro- pyranor3.4-blindol-l-vI)-acetic acid

A. π-Methoxymethyl-1.3.4.9-tetrahydro-pyranor3.4-b1indol-l-yl)-acetic acid.

To a stirred solution of tryptophol (0.8 g, 5 mmol) and methyl 3,4-dimethoxy- 2-butenoate (0.96 g, 6 mmol) in dichloromethane (15 ml, under inert atmosphere) in a 50 ml flask equipped with a magnetic stirrer at room temperature under nitrogen was added dropwise boron trifluoride etherate (0.15 ml, 1.22 mmol). After completion of the reaction (~2 h, monitoring by TLC), the mixture was diluted with 50 ml of dichloromethane and quenched with 50 ml of pH 7 buffer. The layers were separated and the aqueous layer was washed with dichloromethane. The combined organic fractions were washed with brine and dried over sodium sulfate. Purification by flash chromatography (hexane:EtOAc= 3:1) afforded 1.15 g (80%) of colorless crystals that were subjected to hydrolysis in 40 mL of 3:1 mixture MeOH: 1 N NaOH. After the reaction was complete (24 h., monitored by TLC), methanol was removed in vacuo, the mixture was diluted with water (30 mL), and the neutral components were extracted with ethyl acetate (25 mL x 2). The water layer was acidified with 1 N HCl and the product extracted with ethyl acetate (50 mL x 3). The crude material obtained after evaporation of the solvent was redissolved in dichloromethane and precipitated with hexane. Final filtration afforded, after drying, 1.04 g (95%) of the desired product as a solid, m.p. 135-140°C.

Analysis for: C15H.7NO4

Calculated: C, 65.45; H, 6.18; N, 5.09.

Found: C, 64.84; H, 6.25; N, 4.97. lH NMR (400 MHz, DMSO): 5 11.97 (s, 1 H, broad), 10.62 (s, 1 H), 6.9-7.2 (m, 4 H), 3.98 (m, 2 H), 3.6 - 3.8 (dd, 2 H), 3.3 (s, 3 H), 2.8 (dd, 2 H) IR (KBr. cm-1): 3320, 2900, 1700, 1450. MS (El m/z): [M+] 275, 244, 230. B. (l-Methoxymethyl-4-oxo-1.3A9-tetrahvd-ro-pyranor3.4-b]indol-l-yl)-acetic acid.

To a stirred solution at room temperature under nitrogen of (1-methoxymethyl- l,3,4,9-tetrahydro-pyrano[3,4-b]indol-l-yl)-acetic acid methyl ester (0.29 g, 1 mmol) in 5 ml of benzene and 5 ml of pH 4 buffer was .added dropwise over 1.5 h a solution of 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (1.135 g, 5 mmol) in benzene (30 ml).

After 8 h of stirring when the TLC showed ~90% conversion, the mixture was diluted with water (25 ml), ethyl acetate (50 ml), .and sodium sulfite (10 ml of a 10% solution).

The resulting mixture was stirred for ~10 min (until substantial discoloration occurred), and diluted with 1 N NaOH solution (20 ml). Extraction with ethyl acetate (50 ml x 3), followed by evaporation of the solvent gave a light brown powder. Purification by flash chromatography (45:55 ethyl acetate:hexane) afforded 0.195 g (65 %) of methyl ester which gave after hydrolysis (24 h, MeOH- 1 N NaOH), 0.170 g (90%) of the title compound as a solid, m.p. 135-140°C. Analysis for: C15H15NO5

Calculated: C, 63.36; H, 5.65; N, 4.62. Found: C, 61.60; H, 5.16; N, 4.70.

JH NMR (400 MHz, DMSO): δ 12.0 (s, 1 H), 7.18-7.9 (m, 4 H), 4.0-4.4 (dd, 2

H), 3.7 - 3.9 (dd, 2 H), 3.26 (s, 3 H), 2.8-3.2 (dd, 2 H) JE_(KBr, cm"1): 3360, 2900, 1720, 1640, 1460. MS (El): 289, 244.

Figure imgf000018_0001

1.8-Diethyl -4-oxo-1.3.4.9-tetrahvdro-pyrano 13.4-bl indole- 1- acetic acid

A. 1.8-Diethyl- 1.3.4.9- tetrahvdro-pyrano [3.4-bl indole-1- acetic acid methyl ester l,8-Diethyl-l,3,4,9-tetrahydro-pyrano [3,4-b]-l -indole acetic .acid (5.0g, 17.4 mmol) (Demerson et al J. Med. Chem. 19, 391-395 (1976)) was dissolved in MeOH and H2SO4 (2.12 g, 21.6 mmol) was added dropwise. After overnight stirring, the mixture was concentrated, and the precipitate filtered, washed with water, and dried in vacuo to yield the title compound as a solid, 4.68 g, m.p. 130-132°C.

B . 1.8-Diethyl-4-oxo-1.3.4.9-tetrahvdro-pvranor3.4-hlindole-l -acetic acid methyl ester.

The ester produced in step A (0.5g, 1.66mmol) was dissolved in 5 ml of a 90% THF/water solution, and to this was added 2,3-dichloro-5,6-dicyano-l,4-benzo- quinone (0.75 g, 3.3 mmol., previously dissolved in 5 ml THF). This mixture was stirred overnight. The solvent was evaporated and 50 ml of ethyl acetate was added. The organic phase was extracted sequentially with 2.5N NaOH, distilled water and brine. The organic layer was separated, dried (MgSO4) and evaporated to produce 0.56 g of crude oil. The oil was flash chromatographed using CH2Cl2-EtOAc 98-2 as eluant to yield 0.15 g of the desired product as a solid, m.p. 187-189°C. Analysis for: C18 H21 N O4

Calculated: C, 68.55; H, 6.71; N 4.44. Found: C, 68.54; H, 6.55; N, 4.44.

C. 1.8-Diethyl-4-oxo-l .3.4.9-tetrahvdro-pvrano-r3.4-b1 indole- 1 -acetic acid A solution of the product produced in step B (1.25g, 3.9mmol), K2CO3 (3.5g,

25.3mmol) and 60 ml MeOH H2θ 1:1 was refluxed for 3 h. The methanol was evaporated, and the aqueous residue acidified to pH 1 using 6N HCl. The aqueous phase was extracted with EtOAc. The organic phase was washed with water, dried (MgSO4), and evaporated to produce a crude glass which was recrystalli.zed from EtOAc-hexane to afford 1.1 g of the title compound as a solid, m. p. 198-201°C. Analysis for: C17 H19 N O4

Calculate : C, 67.76; H, 6.36; N 4.65. Found: C, 67.38; H, 6.33; N, 4.51. Example 5

Figure imgf000020_0001

(5-Chloro- 1 -ethvl-4-oxo- 1.3.4.9-tetrahvdro-pvranor3.4-hlindol- 1 -ylVacetic acid

To a solution of 5-chloro-l ethyl-l,3,4,9-tetrahydropyrano[3,4-b]indole-l- acetic acid (Demerson et al J.Med. Chem. 19, 391-395 (1976), 0.990g, 3.37 mmole) in meth.anol (30 ml) was added concentrated HCl ( 0.325 g), and the mixture was stirred at room temperature overnight. The methanol was removed and water added to the residue. IN NaOH was added and the mixture extracted with ethyl acetate. The combined extracts were dried (MgSO4), .and concentrated to a gummy solid which was triturated (ethyl acetate- hexane) to afford 0.425 g solid. The solid was dissolved in 9:1 tetrahydrofuran-water (5 ml) and treated with a solution of TEMPO"1" BF4- (0.663 g, 2.72 mmole) in 9:1 tetrahydrofuran-water (5ml). After stirring for one hour, the mixture was concentrated, and water added to the residue. The mixture was extracted with ether, dried (MgSO4) and concentrated to an oil. Flash chromatography (eluting with 95:5 methylene chloride-ethyl acetate) afforded 0.240 g of product which was hydrolyi-ed by treating with IN LiOH (3 ml) and THF (6 ml) overnight. After the .solvent was removed, water was added to the residue and this extracted with methylene chloride. The aqueous layer was acidified (pH 2) and the resulting solid removed, extracted into ethyl acetate, dried (MgSO4), and concentrated. The solid was recrystallized (ethyl acetate-hex.ane) affording a pink powder (0.096 g), m.p. 240- 243°C. Analysis for: C15 H14 CI N O4 Calculated: C, 58.55; H, 4.59; N, 4.55. Found: C, 58.21; H, 4.44; N, 4.41. Example 6

Figure imgf000021_0001

(5-Bromo-l-ethvl-4-oxo-1.3.4.9-tetrahvdro-Pvranor3.4-blindol-l-yl)-acetic acid

A. 4-(3-Bromophenyhvdrazono)-l-butanol

Under anhydrous conditions a solution of 3-bromophenylhydrazine hydrochloride (22.5 g, 100 mmol) and 2,3-dihydrofuran (7.55 ml, 100 mmol) in 200 ml of dry THF was stirred at ambient temperature for 3 h. The reaction mixture was partitioned between EtOAc and H2O. The organic phase was washed with H2O and brine. After drying (Na2SO4), the solvent was evaporated to give 25.6 g of the product as a brown oil. The product was of suitable purity for use in the next step. *H NMR (DMSO-d6, 300 MHz): 3 1.6 (m, 2H, CH2CH2CH2), 2.2 (m, 2H, CHCH2), 3.15 (m, 2H, CH2OH), 6.45+6.8 (m, 2H,vinyl H+ ArH), 7.05 (m, 2H, ArH), 7.2 (m, 1H, ArH), 9.25+9.85 (s, 1H, NH).

B. 1 : 1 Mixture of 4-bromotrvptophol and 5-bromotryptophol Under an atmosphere of nitrogen, a mixture of the crude hydrazone (25.4g,

98.8 mmol, prepared as described in Step A) and zinc chloride (27.2g, 200 mmol) in 200 ml of ethylene glycol was heated at 160 °C for 3 h. Upon cooling the reaction mixture was partitioned between Et2θ and dilute HCl. The organic phase was washed with H2O and brine. After drying (Na2SO4), the solvent was evaporated to afford crude product. Highly polar impurities were removed by dissolving the crude product in CH2CI2 and passing the solution through a pad of silica gel. Removal of the solvent .afforded 22.7 g of a 1 : 1 mixture of 4 and 5 bromo compounds as a brown oil. 1H_NME (DMSO-d6, 300 MHz): θ 2.8 (t, 1H, ArCH2C), 3.05 (t, 1H, ArCH2C), 3.65 (m, 2H, OCH2C), 6.9-7.5 ( , 4H, ArH), 10.9 (s, 0.5H, NH), 11.15 (s, 0.5H, NH). C. 5-Bromo- 1 -ethyl- 1.3.4.9-tetrahvdropyranor3.4-blindole- 1 -acetic acid methyl ester

Under anhydrous conditions, a solution of the mixture of tryptophols (22.6g, 94.1mmol, prepared as described in Step B), and methyl 3 methoxy- 2 pentenoate (13.5, 94.1 mmol) in 200 ml of dry CH2CI2) was treated dropwise with boron trifluoride etherate (13.35g, 94.1 mmol ) via syringe. The solution was stirred at ambient temperature for 2 h, and then washed with saturated NaHCO3 and brine. Upon drying (Na2SO4), the organic phase was passed through a pad of silica gel. The filter cake was washed with additional CH2CI2 and the combined organic layer was evaporated to provide 23 g of product as a mixture of regioisomers. The title compound was isolated via flash chromatography (silica gel, toluene-EtOAc, 9:1) to provide 1.4 g of the title compound, m.p 118-119°C. An additional 3.6 g of product was obtained by recrystallizing the recovered mixed products from Et2θ and petroleum ether .and seeding with pure product. Analysis for: Ci6HigBrNO3

Calculated: C, 54.56; H, 5.15; N, 3.98. Found: C, 54.34; H, 5.07; N, 3.98.

-____M (DMSO-dβ, 400 MHz): δ 0.615 (t, 3H, CCH3), 1.95 (q, 2H, CCH2CH3), 2.76 (d, IH, CCH2CO), 2.96 (m, 3H, CCH2), 3.32 (s, 3H, OCH3), 3.9 (m, 2H, CCH2O), 6.93 (t, IH, ArH), 7.11 (d, IH, ArH), 7.32 ( d, IH, ArH), 11.148 (s, IH, NH)._ MS (m/z, El): 351/353 (M)+, 322/324 (M-C2H5)+, 278/280 (b.p., M-CH2COOH)+.

D. 5-Bromo- 1 -ethyl-4-oxo- 1.3.4.9-tetrahvdropyranor3.4-b]indole- 1 -acetic acid methyl ester

A solution of the ester (0.352 g, 1.0 mmol, prepared as described in Step C), in 10 ml of CH3CN-H2O ( 9:1, v/v) was added dropwise to a stirred solution of TEMPO- BF4 in 10 mL of CH3CN-H2O ( 9: 1, v/v). Stirring was continued for 3 hours, and the reaction mixture was concentrated in vacuo. The residue was partitioned between Et2θ .and H2O. The organic phase was washed with brine and dried (Na2SO4). Removal of solvent afforded a yellow oil which was purified by flash chromatography (silica gel, hexane- EtOAc 2:1) to give 0.11 g of product as an off white solid. H NMR (DMSO-d6, 400 MHz): θ 0.817 (t, 3H, CCH2CH3), 1.98 (m, IH, CCH2CH3), 2.16 (m, IH, CCH2CH3), 2.93 (d, IH, CCH2CO), 3.19 (d, 2H, CCH2CO), 3.529 (s, 3H, OCH3), 4.23 (q, 2H, CCH2O), 7.15 (t, IH, ArH), 7.41 (d,

IH, ArH), 7.49 (d, IH, ArH), 12.36 (s, IH, NH).

MS (m/z, El): 365/367 (M)+, 336/338 (M-C2H5)+, 276/278 (b.p., M-

CH2COOCH3)+.

E. (5-Bromo- l-ethvl-4-oxo-l .3.4.9-tetrahvdro-pvranor3.4-blindol-l -vl .-acetic acid 0.33 EtOAc + 0.16 Et O A .solution of the ester (0.10 g, 0.27 mmol, prepared as described in Step D) in

3 ml of eth.anol and 1 ml of 1 N NaOH was stirred at ambient temperature overnight. The solvent was evaporated and the residue p∑utitioned between Et2θ .and H2O. The aqueous phase was separated and acidified with 1 N HCl. The mixture was extracted with Et2θ. The organic phase was dried with Na2SO4 and the solvent removed to provide crude product which was recrystallized from Et2θ to afford the title compound

(0.04 g, 44%, white solid). Analysis for: Cι5H14BrNO4 + 0.33 EtOAc + 0.16 Et2O

Calculated: C, 51.82; H, 4.68; N, 3.56.

Found: C, 51.88; H, 4.65; N, 3.47.

1H_NME (DMSO-d6, 400 MHz): 3 0.821 (t, 3H, CCH2CH3), 2.00 ( , IH, CCH2CH3), 2.15 (m, IH, CCH2CH3), 2.82 (d, IH, CCH2CO), 3.08 (d, 2H, CCH2CO), 4.235 (q, 2H, CCH2O), 7.14 (t, IH, ArH), 7.40 (d, IH, ArH), 7.48 (d, IH, ArH), 12.25 (s,lH, COOH), 12.357 (s, IH, NH). MS (m/z, EI):351/353 (M+), 322/324, 306/308.

xample 7

Figure imgf000023_0001

5-Cyano- 1 -ethyl-4-oxo- 1.3.4.9- tetrahydropyranor3.4-blindole- 1 -acetic acid

A. 5-Cyano- 1 -ethyl- 1.3.4.9-tetrahydropyrano[3.4-blindole- 1 -acetic acid methyl ester

Under an atmosphere of nitrogen, a solution of the compound of Example 6 (0.409 g, 1.26mmol) and copper (I) cyanide (0.202 g, 2.27 mmol) in 10 ml of N- methyl-2-pyrrolidinone was heated at 170 °C for 5 h. Upon cooling the reaction mixture was partitioned between EtOAc .and H2O. The mixture was vacuum filtered to remove dark solids. The layers were separated and the organic phase was washed 2 times with H2O and brine. After drying (Na2SO4), the .solvent was evaporated to provide 0.50 g of crude solid which was purified by flash chromatography (silica gel, hexane-EtOAc 2:1) to give 0.145 g of the title compound. lU NMR (DMSO-d6, 400 MHz): 9 0.642 (t, 3H, CCH3), 1.958 (q, 2H, CCH2CH3), 2.78 (d, IH, CCH2CO), 2.86 (m, 2H, CCH2), 2.99 (d, IH, CCH2CO), 3.53 (s, 3H, OCH3), 3.9 (m, 2H, CCH2O), 7.18 (t, IH, ArH), 7.44 (d, IH, ArH), 7.66 ( d, IH, ArH), 11.482 (s, IH, NH).

MS [El, m/z]: 298 (M+), 269 (M-C2H5)+, 225 ( M-CH2CO2Me)+, 195

B. 5-Cyano-l-ethyl-4-oχo- 1.3.4.9-tetrahvdropyranor3.4-b1indole-l -acetic acid methyl ester A solution of the ester (0.155 g, 0.52 mmol, prepared as described in Step A) in 5 ml of CH3CN-H2O ( 9:1 , v/v) was added dropwise to a stirred solution of TEMPO-BF4 in 5 ml of CH3CN-H2O ( 9:1, v/v). Stirring was continued for 48 h and the reaction mixture concentrated in vacuo. The residue was partitioned between Et2θ and H2O. The organic phase was washed with brine and dried (Na2SO4). Removal of solvent provided a yellow oil which was purified by flash chromatography (silica gel, hexane-EtOAc 2: 1) to afford 0.110 g of product as an off white solid.

*H NMR (DMSO-d6, 400 MHz): d 0.837 (t, 3H, CCH3), 1.97+2.17 ( , 2H, CCH2CH3), 2.97 (d, IH, CCH2CO), 3.21 (d, IH, CCH2CO), 3.52 (s, 3H, OCH3), 4.29 (m, 2H, COCH2O), 7.40 (t, IH, ArH), 7.68 (d, IH, ArH), 7.83 ( d, IH, ArH), 12.63 (s, IH, NH).

MS ( El, m/z): 312 (M)+, 283 (M-C2H5)+, 239 ( M-CH2COOCH3)+.

C. 5-Cvano- 1 -ethyl-4-oxo- 1.3.4.9-tetrahvdropyranof 3.4-blindole- 1 -acetic acid

A solution of the ester (0.11 g, 0.35 mmol, prepared as described in Step B), in 3 ml of ethanol and 0.5 ml of 1 N NaOH was stirred at ambient temperature overnight. The solvent was evaporated and the residue partitioned between Et2θ and H2O. The aqueous phase was separated and acidified with 1 N HCl. The mixture was extracted with Et2θ. The organic phase was dried with Na2SO4 and the solvent removed to provide the crude product as an oil. Trituration with Et2θ afforded the title compound (0.061 g, 58%) as a white solid. 1H NM (DMSO-d6, 400 MHz): 3 0.841 (t, 3H, CCH3), 2.01 (m, IH, CCH2CH3), 2.16 (m, IH, CCH2CH3), 2.87 (d, IH, CCH2CO), 3.10 (d, IH, CCH2CO), 4.29 (m, 2H, COCH2O), 7.39 (t, IH, ArH), 7.67 (d, IH, ArH), 7.83 ( d, IH, ArH), 12.29 (s, IH, NH), 12.63 (s, IH, COOH). MS [El, m/z]: 298 (M+), 269 (M-C2H5)+, 253 (b.p).

Example 8

Figure imgf000025_0001

8-Allyl- 1 -ethyl-7-fluoro-4-oxo- 1.3.4.9-tetrahydropyranol 3.4-blindole- 1 -acetic acid

A. 8-Allyl- 1 -ethyl-7-fluoro- 1.3.4.9-tetrahydropyranof 3.4-blindole- 1-acetic acid methyl ester A solution of 8-allyl- l-ethyl-7-fluoro- 1,3,9- trihydropyrano[3,4-b]indole-l- acetic acid (0.2 g, 0.63 mmol, Hughes et al J. Heterocycl. Chem. 27, 2151-2163 (1990)) in 20 ml CH3OH was treated portionwise with a 10% solution of trimethylsilyldiazomethane until a slight yellow color persisted. The solvent was removed to give 0.21 g of the product as a light yellow oil. 1H_EME_(DMSO-d6, 300 MHz): θ 0.6 (t, 3H, CCH2CH3), 1.95 (m, 2H, CCH2CH3), 2.6 (m, 2H, CCH2), 2.78 (d, IH, CCH2CO), 2.95 (d, 2H, CCH2CO), 3.5 (s, 3H, OCH3), 3.6 (d, 2H, CH2CH=CH2), 3.9 (m, 2H, CCH2O), 5.0 (m, 2H, CH2CH=CH2), 5.95 (m, IH, CH2CH=CH2), 6.8 (m, IH, ArH), 7.25 (m, IH, ArH), 10.61 (s, IH, NH).

B. 8-Allyl- l-ethyl-7-fluoro-4-oxo- 1.3.4.9-tetrahvdropyrano 3.4-b1indole- 1 -acetic acid methyl ester

A solution of the ester (0.21 g, 0.63 mmol, prepared as described in Step A), in 10 ml of CH3CN-H2O ( 9:1, v/v) was added dropwise to a stirred solution of TEMPO- BF4 in 10 ml CH3CN-H2O ( 9:1, v/v). Stirring was continued for 2 h and the reaction mixture was concentrated in vacuo. The residue was partitioned between E.2O and H2O. The organic phase was washed with brine and dried (Na2SO4). Removal of solvent provides a yellow oil which was purifi.ed by flash chromatography (silica gel, hexane- EtOAc 2: 1 ) to give 0.18 g of product as an off white solid. *H NMR (DMSO-dA. 400 MHz): 3 0.808 (t, 3H, CCH2CH3), 1.96 (m, IH, CCH2CH3), 2.23 (m, IH, CCH2CH3), 2.91 (d, IH, CCH2CO), 3.266 (d, 2H, CCH2CO), 3.51 (s, 3H, OCH3), 3.66 (d, 2H, CH2CH=CH2), 4.25 (q, 2H, CCH2O), 4.97 (m, 2H, CH2CH=CH2), 5.98 (m, IH, CH2CH=CH2), 7.05 (m, IH, ArH), 7.78 (m, IH, ArH), 11.719 (s, IH, NH). 13C NMR (DMSO-d^. 400 MHz): 3 188.959, 169.335, 158.6097, 156.25, 153.73, 135.64, 135.557, 135.132, 119.998, 119.2099, 1 19.1113, 1 15.46, 110.63... MS ( El, m/z): 345 (M)+ 316 (M-C2H5)+, 272 (b.p., M-CH2COOCH3)+.

C. 8-Allvl-l-ethvl-7-fluoro-4-oxo-1.3.4.9-tetrahvdropvranor3.4-blindole-l -acetic acid

A solution of the ester (0.19 g, 0.55 mmol, prepared as described in Step B), in

3 ml of ethanol and 1 ml of 1 N NaOH was stirred at ambient temperature overnight.

The solvent was evaporated and the residue partitioned between Et2θ and H2O. The aqueous phase was separated and acidified with 1 N HCl. The mixture was extracted with Et2θ. The organic phase was dried with Na2SO4 and the solvent removed to provide 0.12 g of crude product which was recrystallized from Et2θ-hexane to afford the title compound (0.10 g, 55%, mp - 232-234 °C, off white solid).

Analysis for: C18H18FNO4

Calculated: C, 65.25; H, 5.48; N, 4.23. Found: C, 64.97; H, 5.45; N, 4.15.

*H NMR (DMSO-d6, 400 MHz): 3 0.809 (t, 3H, CCH2CH3), 1.99 ( , IH,

CCH2CH3), 2.21 (m, IH, CCH2CH3), 2.79 (d, IH, CCH2CO), 3.17 (d, 2H,

CCH2CO), 3.66 (d, 2H, CH2CH=CH2), 4.255 (q, 2H, CCH2O), 4.97 (m, 2H,

CH2CH=CH2), 5.98 (m, IH, CH2CH=CH2), 7.05 (m, IH, ArH), 7.78 (m, IH, ArH), 11.708 (s, IH, NH), 12.208 (s, IH, COOH).

MS ( El, m/z): 331 (M)+, 302 (M-C2H5)+, 272 (M-CH2COOCH3)+. Example 9

Figure imgf000027_0001

π-Ethvl-4-oxo-2.3.4.9-tetrahvdro-lH-(carhazol-l-vni-acetic acid To a solution of 1 -ethyl- 1,2,3, 4- tetrahydro-carbazole-1 -acetic acid (Asselin et al JMed. Chem .19, 787-792 (1976), 0.289 g (1.12 mmole)) in methanol (10ml) was added concentrated sulfuric acid (0.029 g) and the mixture was stirred at room temperature overnight. The methanol was removed and water added to the residue. IN NaOH was added and the mixture extracted with ethyl acetate. The combined ethyl acetate extracts were dried (MgSO4) and concentrated to the oily ester was dissolved in

9:1 tetrahydrofuran-water (3 ml) and chilled to 0 °C. 2,3 -Dichloro-5,6-dicyano-l,4- benzoquinone (0.130 g, 0.574 mmole) was dissolved in tetrahydrofuran (1.1 ml) and added dropwise to the chilled solution. After 2 h the solvent was removed and the residue taken into ethyl acetate, washed several times with IN NaOH, dried (MgSO4) and concentrated to an oil. Flash chromatography (eluting with 2% ethyl acetate- methylene chloride) affords the ester which was hydrolyzed to the title compound utilizing the method of Example 5 (LiOH, H2O/THF). The title compound was obtained as a white solid (0.077 g), m.p. 214-216°C. Analysis for: Ci6 H17 N O3. Calculated: C, 70.83; H, 6.32; N, 5.16. Found: C, 70.54; H, 6.41; N, 5.10. Example 10

Figure imgf000028_0001

ri.8-Diethvl-4-oxo-2.3.4.9-tetrahvdro-lH-(carbazol-l-vm-acetic acid The title compound was prepared according to the method of Example 9 using 0.490 g ( 1.71 mmole) of l,8-diethyl-l,2,3,4-tetrahydrocarbazole-l -acetic acid (Asselin et al., 3. Med. Chem 19, 787-792 (1976)). The title compound was obtained as a white powder (0.197 g), m.p. 212-214°C. Analysis for: Cj ^i N O^

Calculated: C, 72.22; H, 7.07; N, 4.68. Found: C, 72.29; H, 7.03; N, 4.61

Example 11

Figure imgf000028_0002

r l-Ethvl-8-isopropvl-4-oxo-2-3.4.9-tetrahvdro- 1 HJcarbazol- 1 -vl)l-acetic acid

The title compound was prepared according to the method of Example 9 using 0.490 (1.71 mmole) of l,8-diethyl-l,2,3,4-tetrahydrocarbazole-l -acetic acid (Asselin et al., J.Med. Chem 19, 787-792 (1976)). The title compound was obtained as a light yellow solid (0.027 g, 55%), having a melting point of 240-242°C. Analysis for: C19 H23 N O3

Calculais : C, 72.82; H, 7.40; N, 4.47. EΩun : C, 72.24; H, 7.51; N, 4.26. Example 12

Figure imgf000029_0001

f 1 -Ethyl-5-chloro-4-oxo-2.3 A9-tetrahvdro- 1 H-(carbazol- 1 -yl)1-acetic acid

A. ri-Ethyl-5-chloro-2.3.4.9-tetrahvdro-lH-(carbazol-l-yl)lacetic acid methyl ester A solution of 3-chlorophenylhydrazine (154 mmol) and 27.9 g of methyl 1- ethyl-2-oxocyclohexaneacetate (Asselin et al., J.Med. Chem. 19, 787-792 (1976), 140.6 mmol) in toluene (Dean-Stark trap) was refluxed for 43 hr. Removal of the solvent afforded 56.5 g of the crude hydrazone which was cyclized by refluxing for 1.5 h in 300 ml acetic acid containing 17 ml of BF3 etherate. The reaction mixture was then cooled and poured into 750 ml of ice/water and extracted with 3x200 ml Et2θ. The combined ether extract was washed subsequently with 100 ml H2O, 2x115 ml 0.5 N HCl, 2x 100 ml 2.5 N NaOH (100 ml H2O was added to separate layers) and 115 ml H2O, dried over MgSO4 and evaporated to provide 39.5 g of a red liquid. Column chromatography (silica gel, eluting with CH2CI2) gave a 1 : 1 mixture of the 5 and 7 chloro isomeric esters which were separated by HPLC (hexane/ethyl acetate gradient) to afford the pure 5-chloro ester, m.p. 101-104°C (note the 7-chloro ester was a liquid).

B. f 1 -Ethyl-5-chloro-4-oxo-2.3.4.9-tetrahydro-l H-(carbazol- l-yl)l-acetic acid QASZ_E_Q_ The title compound was prepared according to the method of Example 5 using

0.76 g (2.49 mmole) of l-[ethyl-5-chloro-2,3,4,9-terrahydro-lH-(carbazol-l-yl)]- acetic acid methyl ester, and was obtained as a white solid, 202-205°C. Analysis for: Cl6 H10 C1N O3* 0.4 C4H8O2 Calculated: C, 61.99; H, 5.68; N, 4.11. Found: C, 62.19; H, 5.76; N, 3.90.

MS: (El m/z) [M+J305/307

Figure imgf000030_0001

(l- Ethyl-5.8-difluoro-4-oxo-2.3.4.9-tetrahydro-lH-(carbazol-l-yl))-acetic acid

A. ( 1 -Ethyl-5.8-difluoro-2.3.4.9-tetrahydro- 1 H-(carbazol- 1 -yl))-acetic acid ethyl ester

The title compound was prepared according to the method of Example 12, Step A using 20.6 g (0.104 mole) of methyl- l-ethyl-2-oxo-cyclohexane acetate [(Asselin et si J. Med. Chem. 19, 787-792 (1976)] and 2,5 difluorophenylhydrazine. A crystalline solid (7.35 g, 23%) was obtained having a melting point of 97-99°C. Analysis for: C17 H19 F2 N O2

Calculated: C, 66.44; H, 6.23; N, 4.56 Found: C, 66.15; H , 6.13; N, 4.42

B. (l-Ethyl-5.8-difluoro-4-oxo-2.3,4.9-tetrahvdro-lH-(carbazol-l-yl)-acetic acid The title compound was prepared according to the method of Example 5 using

0.200 g (0.622 mmole) of the ester prepared in Step A. The title compound was obtained as a white powder (0.095 g, 50%) having a melting point of 226-229°C. Analysis for: C16 H15 F2 N O3 Calculated: C, 62.54; H, 4.92; N, 4.56 Found: C, 62.78; H, 5.07; N, 4.23 Example 1

Figure imgf000031_0001

(7.8-Difluoro- 1 -ethvl-4-oxo-2.3.4.9-tetrahvdro- 1 H-(carbazol- 1 -vl))-acetic acid. To a stirred solution at room temperature under nitrogen of (7,8-difluoro-l- ethyl-2,3,4,9-tetrahydro-lH-(carbazol-l-yl))acetic acid methyl ester (prepared from 2,3 difluorophenyl hydrazine according to the method of Example 12, Step A, 0.31 g, 1 mmol) in 5 ml of benzene and 5 ml of pH 4 buffer was added dropwise over 1.5 h, a solution of 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (0.522 g, 2.3 mmol) in benzene (30 ml). After 4 h of stirring when the TLC showed -90% conversion, the mixture was diluted with water (25 ml), ethyl acetate (50 ml), and sodium sulfite (10 ml of a 10% solution). The resulting mixture was stirred for -10 min (until substantial discoloration occurred), and diluted with 1 N NaOH (20 ml). The reaction mixture was extracted with ethyl acetate (50 ml x 3). Evaporation of the solvent gave a light brown powder. Purification by flash chromatography (1:1 ethyl acetate:hexane) afforded 0.240 g (72%) of methyl ester which gave after hydrolysis (24 h, MeOH- 1 N NaOH),

0.200 g (90%) of the desired product as a white solid, m.p. 259-261°C. Analysis for: C16H15NO3F2

Calculated: C, 62.54; H, 4.92; N, 4.56. Found: C, 62.60; H, 5.16 ; N, 3.90.

IH NMR (400 MHz, DMSO) δ 12.30 (s, 1 H), 12.20 (s, 1 H), 7.18 - 7.72 (m, 2 H),

2.75 - 3.05 (dd, 2 H), 2.2 - 2.6 (m, 4 H), 1.88 (m, 2 H). JR (KBr, cm"1): 3240, 2950, 1700, 1660, 1530, 1465 MS (El m/z): 307, 278, 248. Example 15

Figure imgf000032_0001

( 1 - Allyl-5.8-difluoro-4-oxo-2.3.4.9-tetrahvdro- 1 H-(c.arbazol- 1 -vDVacetic acid

A. (l-Allyl-5.8-difluoro-2.3.4.9-tetrahvdro-lH-(carbazol-l-ylY)-acetic acid methyl ester To a solution of methyl- l-allyI-2-oxo-cyclohexane acetate [prepared analogous to J. Med. Chem.19, 787 (1976): 19.68 g, 0.094 mole] in toluene (200 ml) was added 2,5-difluorophenylhydrazine (15g, 0.104 mole). The mixture was refluxed for 24 hours as water was collected in a Dean-Stark trap. The toluene was removed and to the residue was added glacial acetic acid (200 ml) and boron trifluoride diethyl etherate (17.34g, 0.122 mole). After refluxing for one hour, the mixture was poured into ice (500 ml) and extracted with ether. The combined extracts were washed sequentially with water, 0.5N HCl, 0.5N NaOH and water, dried (MgSO4) and concentrated to a dark oil. The oil was purified by passing through a thick pad of silica gel (eluted with 5-15% ether-hexane) to give 8.58 (28%) orange oil which crystallized upon sitting, m. p. 78-80°C.

B. (l-Allyl -5.8-difluoro-4-oxo-2.3.4.9-tetrahvdro-lH-(carbazol-l-vl))-acetic acid methyl ester

A solution of TEMPO+BF4" [Bobbin, J. M., et. al., Heterocycles 30: 1131 (1990); 0.760 g, 3.13 mmole] in 9:1 acetonitrile-water (20 ml) was added dropwise to a solution of the ester prepared according to Step A (0.5g, 1.56 mmole) in 9:1 acetonitrile-water (20 ml). The reaction was stirred at room temperature for 2.5 hours then the solvent was removed. Water was added to the residue and this extracted with ethyl acetate, dried (MgSO4) and concentrated to a solid. Purification of the solid by flash chromatography (eluted with 95:5 methylene chloride-ethyl acetate) afforded a white solid (0.450 g, 86%), m. p. 179-181° C. Analvsis for: C18 H17 F2 N O3 Calculated: C, 64.86; H, 5.14; N, 4.20. Found: C, 64.55; H, 4.98; N, 4.08.

C. ( 1 - Allvl-5.8-difluoro-4-oxo-2.3.4.9-tetra vdro- 1 HJcarbazol- 1 -vm-acetic acid To a solution of the ester prepared in Step B (0.250 g, 0.075 mmole) in tetrahydrofuran (6 ml) was added IN lithium hydroxide (3 ml) and the mixture was stirred overnight. After removing the solvent, water was added to the residue and this was extracted with methylene chloride. The aqueous layer was acidified (pH 2) and the resulting solid collected, taken into ethyl acetate, dried (MgSO4) and concentrated. The residue was recrystallized (ethyl acetate-hexane) to afford 0.120 g (50%) of white solid, m. p. 205-206°C.

Analysis for: C17 H15 F2 N O3

Calculated: C, 63.95; H, 4.74; N, 4.39 Found: C, 63.84; H, 4.57; N, 4.32

Figure imgf000033_0001

(5.8-Difluoro-4-oxo- 1 -propvI-2.3.4.9-tetrahvdro- lHJcarbazol- 1 -vl))-acetic acid

A. (5.8-Difluoro-l-propyl-2.3.4.9-tetrahvdro-lH-(carbazol-l-yI))-acetic acid methyl ester

A mixture of the ester prepared according to Step A of Example 15 (1.0 g, 3.13 mmole) and 10% palladium on carbon (0.050 g) in methanol (30 ml) was shaken on a Parr hydrogenation apparatus starting at 50 psi for 2 h. The catalyst was removed and the filtrate concentrated to yield 0.940 g (94%) of a white solid, m. p. 104-106°C. B. (5.8-Difluoro-4-oxo- 1 -propyl-2.3.4.9-tetrahvdro- 1 H-(carbazol- 1 -vDVacetic acid methyl ester

The title compound was prepared according to the method of Example 15, Step B using 0.855 g (2.66 mmole) of the ester of Step A, as a white solid (0.690 g, 77%) having a melting point of 205-207°C. Analysis for; C18 H19 F2 N O3 ■Calculated: C, 64.47; H, 5.71; N, 4.18. Faun : C, 64.38; H, 5.68; N, 4.10.

C. (5.8-Difluoro-4-oxo- 1 -propvl-2.3.4.9-tetrahvdro- 1 HJcarbazol- 1 -vtt acetic acid

The title compound was prepared according to the method of Example 15, Step C using 0.550 g (1.64 mmole) of the ester produced in Step B. A white solid (0.271 g, 51%) was obtained having a melting point of 236-238°C. Analysis for; 7 H17 F2 N O3

Calculated: C, 63.55; H, 5.33; N, 4.36. Found: C, 63.34; H, 5.25; N, 4.28.

Example V

Figure imgf000034_0001

(5.7-Difluoro-l-propvl-4-oxo-2.3.4.9-tetrahvdro-lH-(carbazol-l-vnVacetic acid.

A. (5.7-Difluoro-l-propvl-2.3.4.9-tetrahvdro-lH-(carbazol-l-vnVacetic acid methvl ester.

A mixture of 2,5-difluorophenylhydrazine hydrochloride (10 mmol), 2-propyl-

2-(methoxycarbonyl)methylcyclohexanone (Asselin et al J .Med. Chem 19, 787-792 (1976), 11 mmol), and sodium acetate (12 mmol) was stirred in methanol (50 ml) for

0.5 - 4 h at room temperature until reaction was complete (monitored by TLC). The residue .after evaporation of the methanol was redissolved in ethyl acetate (100 ml), washed with 1 N HCl (50 ml), pH 7 buffer (50 ml), brine, and dried over sodium sulfate. Evaporation of the solvent afforded essentially pure hydrazone. The latter was dissolved in glacial acetic acid (20 ml) and after addition of boron trifluoride etherate (10-12 mmol), quickly heated to reflux. Stirring at reflux was continued until there was complete consumption of hydrazone (usually 20-45 min). After cooling, the mixture was quenched with saturated sodium bicarbonate solution (100 ml) and extracted with ethyl acetate (2 x 100 ml). The combined organics were washed with brine and dried over sodium sulfate. The crude material that was obtained after evaporation of ethyl acetate was purified by flash chromatography (2-10 % EtOAc/hexane) and used as such in the next step.

B. (5.7-Difluoro-l-propyl-4-oxo-2,3.4.9-tetrahvdro-lH-(carbazol-l-yl))-acetic acid. To a stirred solution at room temperature under nitrogen of (5,7-difluoro-l- propyl-2,3,4,9-tetrahydro-lH-carbazol-l-yl)acetic acid methyl ester (0.32 g, 1 mmol) in 5 ml of ben.zene and 5 ml of pH 4 buffer was added dropwise over 1.5 h, a solution of 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (0.522 g, 2.3 mmol) in benzene (30 ml). After 4 h of stirring when the TLC shows ~90% conversion, the mixture was diluted with water (25 ml), ethyl acetate (50 ml) and 10% sodium sulfite (10 ml). The resulting mixture was stirred for -10 min (until substantial discoloration occurred) and diluted with 1 N NaOH (20 ml). Extraction of the reaction mixture with ethyl acetate (50 ml x 3) followed by evaporation of the solvent gave a light brown powder which was purified by flash chromatography (1:1 ethyl acetate:hexane) to afford 0.210 g (63%) of the methyl ester. Hydrolysis (24 h, MeOH - 1 N NaOH) gave 0.182 g (90%) of the desired product as a white solid, m.p. 250-252°C. Analysis for: C17H17NO3F2 Calculated: C, 62.54; H, 4.92; N, 4.56 . Found: C, 62.15; H, 5.10 ; N, 4.24. lH NMR (400 MHz, DMSO) δ 12.2 (s, 1 H), 12.1 (s, 1 H), 6.8 - 7.1 (m, 2 H),

2.6 - 2.9 (dd, 2 H), 2.0 - 2.3 (m, 2 H), 0.84 (t, 3 H).

IE (KBr, cm-1): 3250, 2950, 1700, 1630, 1450 MS [(-)FAB m/z]: 320 Example 18

Figure imgf000036_0001

n.8-Diethvl-4-hvdroxvimino-1.3.4.9-tetrahvdro-pvrano T3.4-bl indol-l-vll- acetic acid

A. f 1 ■8-Diethvl-4-hvdroxvimino- 1.3.4.9-tetrahvdro-pvrano 13.4-bl indol-l-yll- acetic acid methvl ester The ester of Example 4, Step B (0.5 g, l.όmmol), hydroxylamine hydrochloride (0.17 g, 2.4mmol), and 25 ml pyridine were refluxed for 3.5 h. The reaction mixture was poured into water, extracted with CHCI3. The organic phase was then washed with 1.0N HCl, water, dilute NaHCO3, water, and brine, dried (MgSO4) and evaporated to yield a crude solid which was purified by filtration through a pad of silica gel and celite. The product , 0.33 g was isolated as a solid, m. p. 188-190°C Analysis for: Ci 8 H22 N2 O4 Calculated: C, 65.44; H, 6.71; N, 8.48. Found: C, 65.59; H, 6.80; N, 8.27

B. ri.8-Diethvl-4-hvdroxvimino-1.3.4.9-tetrahvdro-pvrano r3.4-bl indol-1-vll- acetic acid 0.06 ethvl acetate. The product of Step A (0.182 g, 0.55 mmol), K2CO3 (0.1 g, 0.71 mmol) and a MeOH-H2θ mixture (10 ml-1 ml) were refluxed for 3 h. The reaction mixture was cooled to room temperature and the methanol was removed. To the reaction mixture was added 10 ml H2O, which was then acidified using 1 N HCl. The aqueous phase was extracted with EtOAc, which was dried (MgSO4), evaporated and triturated using hexane to yield a solid, m.p. 165-168°C (dec).

Analysis for: C 17 H20 2 O4 .0.06 EtOAc

Calculated: C, 64.38; H, 6.41 ; N, 8.71. Found: C, 64.08; H 6.48; N, 8.21. Example 19

Figure imgf000037_0001

f 1.8-Diethyl-4-(methanesulfonyl-hvdrazono)- 1.3.4.9-tetrahydro- pyrano [3.4- bl indol-1-yn-acetic acid sodium salt.

A. [1.8-Diethyl-4-(methanesulfonyl-hydrazono)-1.3.4.9-tetrahydro-pyranor3.4- bl-indol-1-yll-acetic acid methyl ester.

To the ester of Example 4, Step B (0.5 g, 1.6 mmol) was added 10 ml MeOH, 0.4 ml IN HCl and 0.37 ml H2O. The mixture was stirred one minute followed by .addition of CH3SO2NHNH2 all at once. After overnight stirring, the MeOH was evaporated and additional water was added. This aqueous phase was twice extracted with CH2CI2. The organic phase was concentrated to a crude solid and purified by flash chromatography using CH2θ2-EtOAc 95-5 as eluent. The product 0.33 g, was obtained as a solid m.p. 80-82°C. MS_(EI, m/z): 407 (M)+.

B. n.8-Diethyl-4-(methanesulfonvl-hvdrazono1-1.3.4.9-tetrahvdro-pyranor3.4- bl-indol-l-vll-acetic acid sodium salt.

The title compound was prepared according to the method of Example 18, Step B using 0.2 g (0.49 mmol) of the ester from Step A. Trituration in ethyl ether gave the product 0.12 g, as a solid, m.p. 187-190°C. MS [(-)FAB m/z]: 392 (M)+. Example 20

Figure imgf000038_0001

( 1 ,8-DiethyI-4-hydroxyimino-2.3.4.9-tetrahydro- 1 H-carbazol- 1 -y D-acetic acid The title compound was prepared according to the method of Example 18, using of the ester from Example 10. The title compound was obtained as a white solid, m.p. 203-206°C. Analysis for: CI8 H22 N2 O3 Calculated: C, 68.77; H, 7.05; N, 8.91. Found: C, 68.40; H 7.11 ; N, 8.82.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula I having the structure
Figure imgf000039_0001
wherein
R l , R2, R3 and R4 are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms;
R5 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms; R6 is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;
X is oxygen or methylene; A is NZ;
Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonyamino of 1 -6 carbon atoms; or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, wherein R5 is hydrogen or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2, wherein R5 is alkyl of 1 -6 carbon atoms, alkenyl of 1-6 carbon atoms, or alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1, which is [l,8-diethyl-4-hydroxyimino- 1,3,4,9-tetrahydro-pyrano [3,4-b] indol-1-yl]- .acetic acid or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1, which is [l,8-diethyl-4-(methanesulfonyl- hydrazono)-l,3,4,9-tetrahydro-pyrano [3,4-b] indol-l-yl]-acetic acid sodium salt.
6. The compound according to claim 1, which is (l,8-diethyl-4-hydroxyimino- 2,3,4,9-tetrahydro-lH-carbazol-l-yl)-acetic acid or a pharmaceutically acceptable salt thereof.
7. A method of treating arthritic disorders in a mammal in need thereof which comprises .administering to said mammal an effective amount of a compound of formula I having the structure
Figure imgf000040_0001
wherein
Rl, R2, R3 and R4 are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms;
R5 is hydrogen, .alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms; R6 is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;
X is oxygen or methylene; A is NZ;
Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonyamino of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof.
8. A method of treating colorectal cancer in a mammal in need thereof which comprises .administering to said mammal an effective amount of a compound of formula I having the structure
Figure imgf000041_0001
wherein
Rl, R2, R3 and R4 are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms; R5 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the .alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms; R6 is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms; X is oxygen or methylene;
A is oxygen or NZ;
Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonyamino of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof.
9. A method of treating Al^eimer's disease in a mammal which comprises administering to said person an effective amount of a compound of formula I having the structure
Figure imgf000042_0001
wherein
Rl-. R2, R3 and R4 are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1 -6 carbon atoms;
R5 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the .alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms; R6 is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;
X is oxygen or methylene; A is oxygen or NZ;
Z is hydroxyl, alkoxy, aryloxy, carboxy kyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonyamino of 1 -6 carbon atoms; or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition which comprises a compound of formula I having the structure
Figure imgf000043_0001
wherein
Rl, R2, R3 and R4 are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms; R5 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms; R6 is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms; X is oxygen or methylene; A is NZ;
Z is hydroxyl, alkoxy, aryloxy, carboxy kyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonyamino of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.
11. A process for the preparation of a compound of formula I having the structure
Figure imgf000044_0001
wherein
Rl. R2, 3 and R4 are, each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy of 7 to 12 carbon atoms, trifluroalkoxy, alkanoyloxy of 2-6 carbon atoms, hydroxy, halo, trifluoromethyl, cyano, amino, mono- or di-alkylamino in which each alkyl group has 1-6 carbon atoms, alkanamido of 2-6 carbon atoms, or alkanesulfonamido of 1-6 carbon atoms;
R5 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkoxyalkyl in which each alkyl moiety has 1-6 carbon atoms or alkylcycloalkyl in which the .alkyl moiety has 1-6 carbon atoms and the cycloalkyl moiety has 3-8 carbon atoms; R6 is hydrogen, alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms;
X is oxygen or methylene; A is NZ;
Z is hydroxyl, alkoxy, aryloxy, carboxyalkyloxy of 2-7 carbon atoms, arylamino, or alkylsulfonyamino of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, which comprises
(a) reaction of a compound having the formula I where A is oxygen and Rl, R2, R3, R4, R5, Rg and X are as defined above or a salt thereof with a compound having the formula H2NZ where Z is as defined above to prepare a compound having formula I as illustrated above where A is NZ and R,, R2, R3, R4, R5, R6, and X are as defined above or a salt thereof; or
(b) hydrolysis of a compound having formula I as illustrated above where A, Rj, R2, R3, R4, R5 and X are as defined above and R6 is alkyl of 1-6 carbon atoms or alkenyl of 2-7 carbon atoms so as to form a compound having formula I as illustrated above where A, R,, R2, R3, R4, R5, R6 and X are as defined above and R6 is hydrogen or a salt thereof.
PCT/US1997/012782 1996-07-26 1997-07-22 Pyranoindole and carbazole inhibitors of cox-2 WO1998004527A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US68784996 true 1996-07-26 1996-07-26
US08/687,849 1996-07-26

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP50891698A JP2000515887A (en) 1996-07-26 1997-07-22 Cox-2 in pyranoside indole and carbazole inhibitor
AU4043397A AU4043397A (en) 1996-07-26 1997-07-22 Pyranoindole and carbazole inhibitors of cox-2
NZ33432097A NZ334320A (en) 1996-07-26 1997-07-22 Pyranoindole and carbazole inhibitors of cox-2
IL12803197A IL128031D0 (en) 1996-07-26 1997-07-22 Pyranoindole and carbazole inhibitors of cox-2
BR9710597A BR9710597A (en) 1996-07-26 1997-07-22 P¡rano¡ndol carbazole and COX-2 inib¡dores
EP19970938009 EP0923552A1 (en) 1996-07-26 1997-07-22 Pyranoindole and carbazole inhibitors of cox-2
CA 2261588 CA2261588A1 (en) 1996-07-26 1997-07-22 Pyranoindole and carbazole inhibitors of cox-2

Publications (1)

Publication Number Publication Date
WO1998004527A1 true true WO1998004527A1 (en) 1998-02-05

Family

ID=24762121

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012782 WO1998004527A1 (en) 1996-07-26 1997-07-22 Pyranoindole and carbazole inhibitors of cox-2

Country Status (6)

Country Link
EP (1) EP0923552A1 (en)
JP (1) JP2000515887A (en)
KR (1) KR20000029545A (en)
CN (1) CN1230948A (en)
CA (1) CA2261588A1 (en)
WO (1) WO1998004527A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520282A (en) * 1998-07-09 2002-07-09 ルース エル. シッザー, Methods and compositions for the treatment of chronic lymphocytic leukemia
WO2006082409A3 (en) * 2005-02-03 2006-12-14 Hunter Fleming Ltd Tricyclic cytoprotective compounds
WO2007054739A1 (en) * 2005-11-10 2007-05-18 Merck Sharp & Dohme Limited Tetrahydroindole derivatives for treatment of alzheimer's disease
WO2012142256A2 (en) * 2011-04-12 2012-10-18 The Regents Of The University Of California Modulators of mitochondrial protein import
US8541471B2 (en) 2003-05-07 2013-09-24 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686213A (en) * 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US4927842A (en) * 1989-09-29 1990-05-22 American Home Products Corporation 2,3,4,9-tetrahydro-1H-carbazole acetic acid derivatives, composition and use as anti-inflammatories

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686213A (en) * 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US4927842A (en) * 1989-09-29 1990-05-22 American Home Products Corporation 2,3,4,9-tetrahydro-1H-carbazole acetic acid derivatives, composition and use as anti-inflammatories

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LESLIE G. HUMBER ET AL: "Etodolac,a novel antiinflammatory agent.The syntheses and biological evaluation of its metabolites", JOURNAL OF MEDICINAL CHEMISTRY., vol. 31, no. 9, 1987, WASHINGTON US, pages 1712 - 1719, XP002046067 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520282A (en) * 1998-07-09 2002-07-09 ルース エル. シッザー, Methods and compositions for the treatment of chronic lymphocytic leukemia
US8541471B2 (en) 2003-05-07 2013-09-24 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
WO2006082409A3 (en) * 2005-02-03 2006-12-14 Hunter Fleming Ltd Tricyclic cytoprotective compounds
WO2007054739A1 (en) * 2005-11-10 2007-05-18 Merck Sharp & Dohme Limited Tetrahydroindole derivatives for treatment of alzheimer's disease
US8203004B2 (en) 2005-11-10 2012-06-19 Merck, Sharp & Dohme Limited Tetrahydroindole derivatives for treatment of alzheimer's disease
WO2012142256A2 (en) * 2011-04-12 2012-10-18 The Regents Of The University Of California Modulators of mitochondrial protein import
WO2012142256A3 (en) * 2011-04-12 2013-01-17 The Regents Of The University Of California Modulators of mitochondrial protein import

Also Published As

Publication number Publication date Type
JP2000515887A (en) 2000-11-28 application
CN1230948A (en) 1999-10-06 application
CA2261588A1 (en) 1998-02-05 application
EP0923552A1 (en) 1999-06-23 application
KR20000029545A (en) 2000-05-25 application

Similar Documents

Publication Publication Date Title
US5420289A (en) Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5849780A (en) 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5811432A (en) Azaoxindole derivatives
US4927831A (en) Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6740650B2 (en) Heterocyclic cytotoxic agents
US4775680A (en) Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
US3896145A (en) Carbazoles
US6191138B1 (en) Phenanthridines
US20050004156A1 (en) Kinesin inhibitors
US4808608A (en) Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5614532A (en) Quinolone derivatives
US6214838B1 (en) Thienodipyridine derivatives, production and use thereof
US20050143371A1 (en) Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
WO2001079197A1 (en) ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ)
WO1991006537A2 (en) Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole- alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
WO1992001675A2 (en) Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene b4 antagonist activity, their preparation and use in pharmaceutical compositions
US4717725A (en) Ophthalmic wound healing with aldose reductase inhibitors
WO2003070686A1 (en) Substituted phenylalkanoic acid derivative and use thereof
JPH0687746A (en) Antitumor agent
WO1995027714A1 (en) Active compounds
US3856967A (en) Novel indoles in the treatment of pain
EP0162695A1 (en) 6-Oxygenated-1,3,,4,5-Tetrahydrobenz(cd)indol-4-amines
US6214839B1 (en) Substituted 6-alkylphenanthridines
EP0175551A1 (en) Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
WO2004014862A1 (en) Nitro and amino substituted heterocycles as topoisomerase i targeting agents

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2261588

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2261588

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/000882

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1997938009

Country of ref document: EP

Ref document number: 1019997000603

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 334320

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997938009

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997000603

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997938009

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997000603

Country of ref document: KR